Treatment options for prostate cancer: Evaluating the evidence

被引:0
|
作者
Bhatnagar, V
Kaplan, RM
机构
[1] Vet Affairs San Diego Healthcare Syst, Hlth Serv Res & Dev, La Jolla, CA 92161 USA
[2] Univ Calif San Diego, Dept Family & Prevent Med, Sch Med, San Diego, CA 92103 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Hlth Serv, Los Angeles, CA 90024 USA
[4] RAND Corp, Santa Monica, CA 90406 USA
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Controversy surrounds the management options for localized prostate cancer-conservative management, prostatectomy, and radiation. Choosing among these options is difficult because of long-term side effects that include sexual, urinary, and bowel dysfunction. Some recent studies suggest that patients who have chosen treatment (i.e., radical prostatectomy or radiation) have longer disease-free survival compared with patients who have chosen conservative management (i.e., watchful waiting). However, several biases may artificially enhance the perceived value of treatment and make the interpretation of studies on treatment outcomes difficult. Sources of bias include lead time, length time, and patient selection. Because of the uncertain efficacy of management options and the risk of long-term treatment complications, family physicians need to engage their patients in the decision-making process. Copyright (c) 2005 American Academy of Family Physicians.
引用
收藏
页码:1915 / 1922
页数:8
相关论文
共 50 条
  • [21] Gynecomastia in patients with prostate cancer: A review of treatment options
    McLeod, DG
    Iversen, P
    UROLOGY, 2000, 56 (05) : 713 - 720
  • [22] New treatment options for patients with metastatic prostate cancer
    Snoeks, L. L.
    Ogilvie, A. C.
    van Haarst, E. P.
    Siegert, C. E. H.
    NETHERLANDS JOURNAL OF MEDICINE, 2013, 71 (06): : 290 - 294
  • [23] Gynecomastia in patients with prostate cancer: update on treatment options
    Autorino, R.
    Perdona, S.
    D'Armiento, M.
    De Sio, M.
    Damiano, R.
    Cosentino, L.
    Di Lorenzo, G.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (02) : 109 - 114
  • [24] Treatment options for hormone-refractory prostate cancer
    Heidenreich, A
    Ohlmann, CH
    UROLOGE, 2005, 44 (11): : 1303 - +
  • [25] Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer
    Steven B. Zeliadt
    David F. Penson
    PharmacoEconomics, 2007, 25 : 309 - 327
  • [26] Expanding Treatment Options for Older Adults With Prostate Cancer
    Morgans, Alicia
    JAMA ONCOLOGY, 2023, 9 (12) : 1638 - 1639
  • [27] Gynecomastia in patients with prostate cancer: update on treatment options
    R Autorino
    S Perdonà
    M D'Armiento
    M De Sio
    R Damiano
    L Cosentino
    G Di Lorenzo
    Prostate Cancer and Prostatic Diseases, 2006, 9 : 109 - 114
  • [28] Low and intermediate risk prostate cancer: Treatment options
    Minana-Lopez, Bernardino
    Reina-Alcaina, Leandro
    Rivero-Guerra, Angela
    Rosino-Sanchez, Antonio
    Izquierdo-Morejon, Emilio
    Pietricica, Bogdan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (06): : 260 - 270
  • [29] A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer
    Moussa, Mohamad
    Papatsoris, Athanasios
    Sryropoulou, Despoina
    Chakra, Mohamed Abou
    Dellis, Athanasios
    Tzelves, Lazaros
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (13) : 1685 - 1728
  • [30] Novel focal therapy treatment options for prostate cancer
    Werntz, Ryan P.
    Eggener, Scott E.
    CURRENT OPINION IN UROLOGY, 2018, 28 (02) : 178 - 183